347 results about "Amyloidogenic Proteins" patented technology

The invention discloses a cognitive improvement method and system based on multi-modal data. The cognition improvement method comprises the following steps: acquiring first multi-modal data of a patient before treatment; carrying out amyloid protein load grouping on the patients on the basis of amyloid protein loads in the brains of the patients so as to obtain corresponding initial cognitive training schemes; performing cognitive training based on the initial cognitive training scheme during the treatment period of the patient, and collecting second multi-modal data during the treatment period; based on the multi-modal data before and after the treatment of the patient, acquiring multi-modal change data of the patient in combination with the brain network group atlas; and inputting the multi-modal change data of the patient into a preset model to output a cognition improvement scheme for improving the cognition index of the patient to the greatest extent, and pushing the cognition improvement scheme to the patient for cognition training. According to the method, by integrating A beta-PET data, functional nuclear magnetic resonance imaging data and event-related potential data, the neuroplasticity change of a patient is evaluated in real time, so that a personalized cognition improvement scheme is dynamically generated.

The invention discloses an amyloid-like protein mediated base material surface controllable functional modification method, which comprises the following steps of: dip-coating or spraying an aqueous solution containing protein, a photoinitiator, an anti-fouling monomer and an adhesive monomer on the surface of a base material, and irradiating by ultraviolet rays to form a uniform anti-fouling amyloid protein nano coating on the surface of the base material. Functional monomers and amyloid protein self-assembly are combined, and the effects of adhesion and stubborn stain resistance can be achieved by simultaneously constructing a dual-adhesion unit and a functional anti-fouling unit. The protein nano coating has high optical permeability, on the premise that the original appearance of a base material is not affected, the functions of surface stubborn stain resistance, self-cleaning, stable adhesion and the like are added, stains on the surface of the coating can be washed away through simple water flow washing, and the protein nano coating has wide application prospects in daily life.

The invention provides a soybean amyloid protein fiber, a preparation method thereof, a high internal phase emulsion and application, and belongs to the technical field of protein fibers. The preparation method comprises the following steps: dissolving soybean protein isolate in water, adjusting the obtained soybean protein isolate solution to a first pH value, carrying out ultrasonic treatment and / or first stirring treatment, adjusting the obtained feed liquid to a second pH value, sequentially carrying out second stirring treatment, dialysis and freeze drying, and dissolving the obtained pretreated soybean protein isolate in water, adjusting the pH value of the pretreated soybean protein isolate solution to a third pH value, and sequentially performing hydration treatment and fiber growth treatment to obtain the soybean amyloid protein fiber. The invention provides a soybean amyloid protein fiber preparation method based on ultrasonic pretreatment and / or pH migration pretreatment. The yield and the emulsifying property of the obtained soybean amyloid protein fiber can be remarkably improved.

The invention provides a serum amyloid A determination kit as well as preparation and application thereof, the kit optimizes and screens components and concentrations of buffer systems and inorganic salts in a reagent 1 and a reagent 2, particularly adds polyanions and DSS, and uses a quenching agent in the preparation process of anti-SAA antibody coated latex particles. According to the kit prepared by optimizing and screening the components, the specific recognition and binding capacity to the serum amyloid protein A is remarkably improved, the performance indexes such as the sensitivity, the linear range, the anti-interference capacity, the stability and the repeatability of the kit are improved, the linearity of a detection value in the linear range of 2mg / L to 500mg / L is good, the detection value is accurate and usable, and the kit is suitable for being used in the field of detection of the serum amyloid protein A. Therefore, the comprehensive performance of immunoassay on the serum amyloid protein A is improved.

The invention provides a bumetanib derivative as well as preparation and application thereof, and relates to the field of medicinal chemistry. According to the invention, bumetanib is taken as a basic structural framework, D-pinitol is taken as an organic ligand for structural modification, and the bumetanib derivative with the structural formula (I) is finally obtained. The bumetanib derivative provided by the invention can effectively inhibit abnormal aggregation of beta-amyloid protein and remarkably delay the CL4176 nematode paralysis process, and has the prospect of being developed into a medicine for resisting beta-amyloid protein related diseases such as Alzheimer's disease.

The invention relates to the field of breeding technical equipment, and particularly provides protein expression profile screening and application of anxiety disorder of Alzheimer's disease. Specifically, for Alzheimer's disease anxiety disorder caused by amyloid beta protein accumulation, proteomics analysis finds that inhibition of aBLA-vCA1 pathway functions can effectively relieve social avoidance behaviors caused by amyloid beta protein accumulation; and the differential functional proteins of the anxiety disorder of the Alzheimer's disease, such as RPS6, UBQLN1, Eras2, Rpl30, SERBP1, CLU, APOE, C4B, C1QB, C1QA, C1QC, MAPK1, MAPK3, RHOG, PTK2B, ASPA, GAD1, GAD2, H3f3a, H4C8 and TSPYL4, are screened out. The different functional proteins can be used as biomarkers for detecting Alzheimer's disease anxiety disorder caused by accumulation of pulverulent beta protein, and can be used as potential therapeutic targets.

The invention provides a plant amyloid protein fiber, a preparation method thereof, a composite film and a composite coating preservative, and belongs to the technical field of protein fibers. The method comprises the following steps: mixing plant protein isolate with water, adjusting the pH value to 1.5-2.5, then carrying out solid-liquid separation, and carrying out fiber growth treatment on the obtained liquid material containing the plant protein to obtain the plant amyloid protein fiber; according to a growth kinetic curve, the fiber growth treatment comprises first incubation treatment, ultrasonic treatment and second incubation treatment in sequence, the time of the first incubation treatment is 0 h to the end of the logarithmic phase, and the first incubation treatment and the second incubation treatment are carried out under a non-ultrasonic condition; when the time of the first incubation treatment is 0 h, the ultrasonic power density of the ultrasonic treatment is greater than or equal to 2.5 W / mL. According to the method, the growth process and morphology of the fibers can be conveniently and simultaneously regulated, and the proportion of rigid fibers can be reduced.

The invention provides a monoclonal antibody capable of specifically recognizing a specific metabolic fragment of human amyloid protein and application of the monoclonal antibody, and belongs to the technical field of genetic engineering. The invention provides a hybridoma cell strain AB5H, and the preservation number of the hybridoma cell strain AB5H is CCTCC (China Center For Type Culture Collection) NO: C201255. The hybridoma cell strain AB5H disclosed by the invention can secrete a monoclonal antibody which has relatively high activity and can specifically recognize human beta amyloid protein A beta 40; the monoclonal antibody is high in titer, can be used as a capture antibody, and is used for preparing a human Abeta40 protein quantitative detection kit and quantitatively detecting the content of Abeta40 in cerebrospinal fluid and blood, so that the detection result deviation caused by the fact that the content of Abeta40 in peripheral blood is easily influenced by metabolism, sample treatment conditions and methods and individual differences is overcome, and the detection accuracy is improved. The variation degree of a detection result is reduced, so that a judgment boundary value of a blood A beta detection result is conveniently obtained, and AD early diagnosis is realized.

The invention discloses a chemiluminescent probe of a targeted A beta oligomer as well as a preparation method and application of the chemiluminescent probe. The structural general formula of the chemiluminescent probe of the targeted A beta oligomer is shown as I in the specification. According to the present invention, the chemiluminescence probe capable of specifically targeting the A beta oligomer is successfully constructed for the first time so as to achieve the early diagnosis and treatment of AD; an additional light source is not needed, and background signals caused by exciting light can be effectively reduced, so that the detection sensitivity is higher. The chemiluminescent probe targeting the A beta oligomer can promote selective oxygenation of beta amyloid protein through chemical excitation and neutralize toxicity of the A beta oligomer, has certain treatment potential and is expected to be developed into an effective method for treating amyloidosis. # imgabs0 #

The invention relates to the technical field of biological medicines, and particularly discloses a BODIPY (boron dipyrromethene)-based compound and an application of the BODIPY-based compound in photodynamic oxidation of beta-amyloid protein (Abeta). The compound takes iodo-BODIPY as a photosensitive core and is connected with 4-t-butyloxycarboryl benzene as an A beta recognition group. The introduction of iodine atoms significantly enhances the intersystem crossing ability of molecules, so that the molecules have excellent reactive oxygen species (ROS) generation ability. The compound has high ROS yield, good optical stability and biocompatibility, can specifically target A beta aggregate, realizes photodynamic oxidative degradation, and provides a novel potential tool for treatment of Alzheimer's disease.

The present invention discloses a fluorescent probe for detecting Aβ aggregates, its preparation method and applications. Specifically, the structure of the probe is shown in Formula I. The Aβ aggregate probe provided by the present invention has various uses, can be used for the recognition and detection of Aβ aggregates in vitro and in biological tissue sections, is used for β-amyloid protein imaging in biological tissues with high sensitivity, and has wide applications in the early diagnosis of Alzheimer's disease, preclinical research and development of anti-AD drugs, and the revelation of pathological mechanisms.

The invention discloses an amyloid-like protein mediated long-acting metal organic framework antifouling agent as well as a preparation method and application thereof. Belongs to the field of marine antifouling material preparation. The anti-fouling agent is based on MOF with an anti-fouling function, and amyloid-like protein is self-assembled on the surface of the MOF to form a compact protective shell layer. According to the preparation method, metal ions and organic ligands react and are connected through coordinate bonds to form an MOF structure, and MOF particles are obtained through centrifugation, collection, precipitation, washing and drying; under the action of a water-soluble organic reducing substance, the protein completely opens a disulfide bond to form an unfolded protein chain, and the protein chain is self-assembled to obtain an amyloid-like protein solution; and placing the MOF particles in an amyloid-like protein solution, and carrying out simple one-step incubation to obtain the amyloid-like protein mediated long-acting metal organic framework antifouling agent. The antifouling agent is prepared by adopting a novel green, high-stability, rapid and efficient mild modification method, and has the advantages of stability, durability, universality and high efficiency.

Compositions and methods useful to reduce expression of amyloid precursor protein (APP) gene and for treatment of APP-associated diseases and conditions are provided. Provided are APP dsRNA agents, APP antisense polynucleotide agents, compositions comprising APP dsRNA agents, and compositions comprising APP antisense polynucleotide agents that can be used to reduce APP expression in cells and subjects.

The invention discloses a protein / polyphenol composite nanofiltration membrane and application thereof, and belongs to the technical field of protein membrane separation. The nano-filtration membrane is formed by modifying an amyloid-like protein film with the thickness of 50-300 nm and the average pore size of 0.4-1 nm by polyphenol and then adhering the amyloid-like protein film to a porous base material, wherein the amyloid-like protein film is formed by unfolding and self-assembling protein under the action of a modifier. The nanofiltration membrane disclosed by the invention can realize efficient selective separation of Mg < 2 + > / Li < + > in salt lake brine with a high magnesium-lithium ratio, has selective separation capacity on mixed anions Cl <-> / SO4 < 2->, can effectively remove heavy metal ions and perfluoro / polyfluoroalkyl compounds in water, and provides an important basis for developing a sustainable and high-performance next-generation membrane separation technology.

The invention belongs to the technical field of microorganisms, and relates to lactobacillus acidophilus LA4 and application thereof. The classification name of the lactobacillus acidophilus LA4 is lactobacillus acidophilus, the lactobacillus acidophilus LA4 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on July 9, 2025, and the preservation number of the lactobacillus acidophilus LA4 is CGMCC No.35144; the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain can significantly improve cognitive impairment of an elderly behavior cognitive impairment model mouse and enhance the learning and memory ability of the mouse by reducing deposition of beta amyloid protein in the brain of the mouse, inhibiting the activity of acetylcholin esterase, regulating and controlling the neurotransmitter level, relieving brain inflammatory response, reducing nerve injury, promoting synaptic regeneration and the like. The strain provided by the invention provides a potential treatment scheme for preventing or improving senile behavioral cognitive impairment, and has important development and application values.

The invention discloses a flexible friction nano-generator material based on silk fabric and Ecoflex as well as a preparation method and application of the flexible friction nano-generator material. The invention mainly comprises a positive friction layer material SF / beta-LGF / ZnO and a negative friction layer material Ecoflex / Ag-MMT. Specifically, the positive friction layer is prepared through the following steps that firstly, beta-lactoglobulin is converted into amyloid fibril at the specific pH and temperature, then beta-LGF is loaded on the surface of silk fabric through a cross-linking agent, and a ZnO film grows on the surface of the silk fabric through the atomic layer deposition technology. The negative friction layer is based on biodegradable Ecoflex, and the electrical property of the negative friction layer is improved by doping Ag intercalated montmorillonite. According to the invention, not only are the electron donating and electron withdrawing capabilities of the silk fabric and Ecoflex enhanced, but also the electric output performance of the friction nano-generator is remarkably improved, and low-frequency mechanical energy can be efficiently converted into electric energy.

The present invention relates to an artificial intelligence-based device and method for determining amyloid PET positivity, wherein a normal-appearing white matter dominance ratio is used and amyloid PET positivity is automatically determined based on machine learning, thereby improving the accuracy and sensitivity of amyloid PET positivity determination. The device comprises: an image acquisition unit for acquiring PET and MRI images of the brain of a diagnostic subject administered with a contrast agent, the images being acquired through tomographic scanning; a segmentation unit for segmenting normal-appearing white matter (NAWM) and white matter hyperintensity (WMH) from a fluid attenuated inversion recovery (FLAIR) image obtained from the MRI image; a standardized uptake value ratio (SUVR) calculation unit for calculating a global standardized uptake value ratio (SUVR) and a standardized uptake value ratio in normal-appearing white matter (NAWM SUVR), on the basis of the PET image and the NAWM region segmented by the segmentation unit; and an amyloid PET positivity determination unit for determining amyloid PET positivity by inputting the global SUVR and the NAWM dominance ratio (NDR) into a pre-trained prediction model, wherein the NDR is a value obtained by dividing the global SUVR by the NAWM SUVR.

The present invention relates to an improved antibody specifically binding to amyloid-β oligomers (AβOs). Specifically, the present invention relates to an improved form of the antibody W20. Compared with the antibody W20, the improved form of the antibody W20 has a significantly improved affinity to AβOs, and can more significantly inhibit the aggregation of Aβ and the AβOs-induced toxicity of nerve cells, more effectively improve the cognition and memory functions of an Alzheimer's disease model mouse, and reduce pathological changes in the brain of the mouse. The improved form of the antibody can specifically bind to oligomers of an amyloid-β, α-synuclein, mHTT and SOD 1, can inhibit the aggregation and cytotoxicity of various amyloids, and has a better potential for treating various amyloid diseases, such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, than the antibody W20. The improved form of the antibody can specifically bind to a highly toxic amyloid protein oligomer Aβo*3F, and has a better AD diagnosis value. The amino acid sequence of the antibody W20 is as shown in SEQ ID NO: 1.

The invention discloses a method for detecting beta-amyloid protein in urine by magnetic particle chemiluminescence based on acridinium ester. The method comprises the following steps: (1) coupling carboxyl magnetic beads with an A beta 42 N-terminal antibody; (2) labeling acridinium ester and a Lec antibody; and (3) respectively diluting the A beta calibrator, the urine sample to be detected, the magnetic bead compound and the acridinium ester-Lec antibody compound, and carrying out luminescence detection on a luminescence instrument.

The invention discloses a silent pituitary ACTH cytoma identification method. The method comprises the following steps: determining a pituitary neuroendocrine tumor through imaging examination; a serum marker SAA (serum amyloid protein A) index is obtained through blood detection; constructing a silent pituitary ACTH cytoma recognition model by combining serum marker SAA indexes, age, gender, clinical symptoms and various hormone variable characteristics of pituitary; and identifying and judging the silent pituitary ACTH cytoma according to the identification model. The serum SAA is used as an index for identifying the silent pituitary ACTH cytoma, and the serum SAA is used as a mature serum detection index in clinical application, so that a doctor can accurately identify a high-risk subtype of the silent pituitary ACTH cytoma which is a pituitary neuroendocrine tumor, and can adjust an operation strategy according to factors such as invasiveness and recurrence risk of the tumor; therefore, the operation effect is improved, and patient prognosis is improved.

The invention discloses a serum amyloid protein A immunochromatography detection reagent strip which comprises a reaction bottom plate, a sample pad, a combination pad, a chromatography membrane and absorbent paper, the chromatography membrane is arranged in the middle of the reaction bottom plate, the sample pad and the absorbent paper are arranged at the two ends of the reaction bottom plate respectively, the chromatography membrane is arranged in the middle of the reaction bottom plate, the combination pad is arranged between the chromatography membrane and the sample pad, the sample pad is partially overlapped on the combination pad, and the combination pad is partially overlapped on one side of the chromatography membrane. The absorbent paper is partially overlapped on the other side of the chromatography membrane; quantum dot fluorescent microspheres used for serum amyloid protein A antibody labeling and quantum dot fluorescent microspheres used for DNP-BSA labeling are solid-phase on the combination pad; the chromatographic membrane is provided with a detection line coated with a serum amyloid protein A detection antibody and a quality control line coated with a rabbit anti-DNP quality control antibody; and a detection line and a quality control line are sequentially arranged on the chromatography membrane in parallel at intervals along the chromatography direction. The invention further discloses a corresponding preparation method, a detection kit, a detection method and application.

The invention belongs to the technical field of biochemistry, and discloses a chemiluminescent probe responding to beta amyloid protein as well as a preparation method and application thereof. The structural formula of the probe is shown in the specification. According to the probe designed by the invention, the near-infrared chemiluminescence capability (gt; 650nm) is realized through an extended conjugated structure; meanwhile, high selectivity on A beta is realized by introducing a heteroatom conjugate pi bridge.

The present invention relates to a composite material comprising at least one textile commodity polymer and protein fibers comprising at least one amyloid structure. The invention also relates to a method for preparing such a material, as well as to the use of such a material for adsorbing a pollutant or extracting metal ions.

Peptide compounds derived from cathepsin G (CG), neutrophil elastase (NE), and cationic antimicrobial protein of 37 kDa (CAP37), and methods of their use in inhibiting and / or reversing polymerization of amyloid β peptide into oligomers and / or fibrils, and / or disaggregating amyloid β plaques, and methods of use of the peptide compounds in treatments of, for example, Alzheimer's disease, cerebral amyloid angiopathy, dementia, and / or neuroinflammation, and / or symptoms thereof are disclosed.

The application provides a plant amyloid protein fiber and a preparation method and a composite film and a composite coating film preservative thereof, and belongs to the technical field of protein fibers. Plant protein isolate is mixed with water, and after the pH value is adjusted to 1.5-2.5, solid-liquid separation is carried out, the obtained plant protein-containing liquid material is subjected to fiber growth treatment, and a plant amyloid protein fiber is obtained. According to the growth kinetics curve, the fiber growth treatment comprises sequentially performing first incubation treatment, ultrasonic treatment and second incubation treatment, the time of the first incubation treatment is 0 h-end of the logarithmic growth phase, and the first incubation treatment and the second incubation treatment are performed under non-ultrasonic conditions. When the time of the first incubation treatment is 0 h, the ultrasonic power density of the ultrasonic treatment is greater than or equal to 2.5 W / mL. The method is convenient for simultaneously regulating the growth process and morphology of the fiber, and can reduce the proportion of rigid fibers.

The present invention provides a novel anti-Aβ antibody capable of detecting an Aβ related peptide, a method for measuring an Aβ related peptide in a biological sample by immunochemically using the above-mentioned novel anti-Aβ antibody, and a kit. A monoclonal antibody that recognizes an Aβ related peptide, and is produced by a hybridoma deposited under the accession number NITE BP-02998 at the NITE Patent Microorganisms Depositary of the National Institute of Technology and Evaluation. An antibody-immobilized carrier that includes a carrier and the monoclonal antibody defined in claim 1 bound to the carrier. A kit for measuring an Aβ related peptide, comprising the antibody-immobilized carrier.

The present invention relates to a cell-penetrating peptide and its derivatives to inhibit α-synuclein fibrillation. The present invention specifically relates to a peptide-based inhibitor of Parkinson's Disease. The present invention discloses the identification of the peptides permeable to blood brain barrier for inhibition. α-synuclein fibril formation is observed in the presence of peptides as indicated by SEQ. ID-7, SEQ. ID-8 wherein the SEQ. ID-7, SEQ. ID-8 are truncated versions of SEQ. ID-4 having the homology of 83% and 75% respectively. It provides a peptide having an amino acid sequence of Formula 1. The present invention also provides a pharmaceutical composition comprising a peptide of Formula 1 along with the pharmaceutically acceptable excipient(s) having inhibitory activity against β-sheet polymerisation of amyloidogenic proteins. The analysis showed that peptides corresponding to SEQ. ID-7, SEQ. ID-8 are better inhibitors than SEQ. ID-4 against α-synuclein fibrillation.

The present invention provides a compound having an effect of inhibiting the production of β-amyloid protein, especially an effect of inhibiting BACE1, and the compound can be used as a therapeutic agent or preventive agent for diseases induced by the production, secretion and / or deposition of β-amyloid protein. A compound of formula (I), wherein R 3 Each independently is an alkyl group optionally substituted by halogen, cyano, alkoxy, haloalkoxy or non-aromatic carbocyclic group, etc.; t is an integer of 0-3; R 5 is a hydrogen atom or a halogen; R 6 is selected from a hydrogen atom, a halogen and a substituted or unsubstituted alkyl group; Ring B is a substituted or unsubstituted pyrazine, etc.; or a pharmaceutically acceptable salt thereof.

The present invention discloses a β-amyloid protein probe and a preparation method and application thereof. The skeleton of the β-amyloid protein probe can effectively increase the ICT effect of the probe, so that the probe has a larger emission wavelength and a larger fluorescence intensity enhancement factor before and after binding to the Aβ protein. At the same time, it uses a nitrogen-containing six-membered aromatic ring as an electron acceptor, which not only has better electron-withdrawing ability, but also the large steric hindrance of the electron acceptor after the probe enters the hydrophobic cavity of the Aβ protein can strengthen the restriction on molecular torsion, and trigger a more efficient ICT effect with the thiophene-containing π bridge. At the same time, this type of nitrogen-containing six-membered aromatic ring can combine well with the β-sheet structure of the Aβ protein, effectively improving the binding ability of the probe to the Aβ protein and the Aβ protein selectivity. Therefore, the probe can be used for labeling Aβ protein and preparing an imaging agent for labeling Aβ protein.

Compounds, systems, kits, methods, and / or apparatuses may be operative to reduce amyloid beta (Aβ) peptide in a patient, including a central nervous system (CNS) of the patient and / or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a Aβ displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds Aβ (for instance, Aβ peptide or non-plaque Aβ) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free Aβ peptide (for instance, Aβ monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and / or artificial processes, such as dialysis. Increased removal of the free Aβ peptide in the periphery may ultimately lead to less Aβ peptide in the CNS, which may decrease Aβ plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.